thymectacin

Thymectacin is a small molecule phosphoramidate prodrug of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU), developed as an experimental anticancer agent. It is selectively active against tumor cells that overexpress thymidylate synthase (TS), an enzyme critical for DNA biosynthesis and frequently upregulated in many solid tumors. Thymectacin is converted intracellularly by TS to bromovinyldeoxyuridine monophosphate (BVdUMP), which competes with the natural substrate deoxyuridine monophosphate for binding to TS. Unlike traditional TS inhibitors, thymectacin acts as a reversible substrate for TS catalysis; the enzyme retains activity and converts BVdUMP into cytotoxic metabolites that disrupt DNA synthesis in rapidly dividing tumor cells. This selectivity allows targeted killing of cancer cells while sparing normal tissue. Thymectacin was initially developed by NewBiotics and later Kiadis Pharma BV; it entered phase I clinical trials for colon cancer but development has since been discontinued[1][2][3][5].

Brand names

Thymectacin

Other names

brivudine phosphoramidateBVDU prodrugN-[[5-[(E)-2-Bromovinyl]-2'-deoxyuridin-5'-O-yl]](phenoxy)phosphoryl]-L-alanine methyl ester